No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-07-19. Consecutive prior reports dated 2026-07-11, 2026-07-03, and 2026-06-25 similarly noted the absence of material corporate news events within their respective windows [Brief - 2026-07-11] [Brief - 2026-07-03] [Brief - 2026-06-25].
Amgen's trailing twelve-month revenue stood at $37.22 billion as of 2026-03-31, reflecting year-over-year growth of 5.76%. Net income for the same period was $7.80 billion, representing a net margin of 20.96%. Gross margin was recorded at 48.58% and operating margin at 28.39%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. Market capitalisation was approximately $197.69 billion, with a P/E ratio of 25.49 [SEC 10-Q - AMGN - 2026-03-31].
Institutional ownership changes were the primary trigger for this report. Bridgewater added 389% to its reported AMGN position, while Millennium added 47% to its holding. In contrast, AQR Capital reduced its position by 30% and Citadel reduced its position by 9.4% [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Citadel - Q1 2026].
The 10-year US Treasury yield stood at 4.57% and the 2-year yield at 4.16% at the time of this report's generation, reflecting a normal yield curve shape [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for a company carrying $59.32 billion in total debt, as refinancing conditions and cost of capital remain factors in assessing balance sheet composition [SEC 10-Q - AMGN - 2026-03-31].